Compass Therapeutics
$CMPX Bull vs Bear (quick take)
Bull Case
• Cash: ~$180M on balance sheet
• Quarterly burn: ~$15–18M
• Runway: ~40–48 months (no near-term dilution pressure)
• Data is confounded, but efficacy signal is strong
• No approved alternatives → significant unmet need
• FDA fast track designation = ongoing dialogue + urgency
Bear Case
• FDA has previously denied based on crossover/confounded data
• Trial design issues still create regulatory risk
Conclusion
Bull case wins. In a setting with no treatment options, FDA often leans toward patient access. The drug appears to work and extend life. If they can address the data concerns, upside is asymmetric relative to risk.
thinefloof
tell your AI to go make me a sandwich
4
EvanCZHunter
next let's have a poll on which horizon will have the sunrise tomorrow. My money is on East!!!